Related Experiment Video
Updated: Jun 19, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors
Abstract:
Erectile dysfunction (ED) is one of the most challenging complications associated with radical prostatectomy (RP) for clinically localized prostate cancer. Currently, a broad spectrum of therapeutic options are available to improve sexual health after surgical treatment. Several basic science reports highlighted a potential role for phosphodiesterase type 5 inhibitors in the prevention of endothelial damage related to ischemia reperfusion and/or denervation following surgery. Recent studies have shown that pharmacological prophylaxis soon after RP can significantly improve the rate at which erectile function is recovered after surgery. Use of on-demand treatments for ED in patients who have undergone RP has been shown to be highly effective. In this context, pharmacological prophylaxis potentially may have a significantly expanded role in future strategies aimed at preserving postoperative erectile function. We analyzed the factors affecting erectile function after RP and evaluated the evidence suggesting the role of pharmacological prophylaxis and treatment of ED after surgery.
Insights
Phosphodiesterase type 5 inhibitors may help prevent erectile dysfunction (ED) after radical prostatectomy (RP). Early use of these drugs can improve recovery of erectile function post-surgery.
Area of Science:
- Urology
- Oncology
- Pharmacology
Background:
- Erectile dysfunction (ED) is a common complication following radical prostatectomy (RP) for prostate cancer.
- Current treatments for post-RP sexual dysfunction are varied.
- Basic science suggests phosphodiesterase type 5 (PDE5) inhibitors may protect against surgical damage.
Purpose of the Study:
- To analyze factors influencing erectile function after RP.
- To evaluate the evidence for pharmacological prophylaxis and treatment of ED post-RP.
Main Methods:
- Review of scientific literature on ED after RP.
- Analysis of studies on PDE5 inhibitors for ED prevention and treatment.
Main Results:
- Pharmacological prophylaxis with PDE5 inhibitors soon after RP may improve erectile function recovery rates.
- On-demand PDE5 inhibitor treatment is effective for ED in patients post-RP.
- PDE5 inhibitors show potential in preventing endothelial damage from ischemia-reperfusion and denervation.
Conclusions:
- Pharmacological prophylaxis with PDE5 inhibitors is a promising strategy for preserving erectile function after RP.
- Further research may expand the role of PDE5 inhibitors in post-prostatectomy sexual health management.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Peripheral Artery Disease V: Postoperative Nursing Management
